PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan

Keros Therapeutics, Inc. (KROS) Sharpe Ratio: -0.39

Equity · Currency in USD · Last updated Jun 23, 2026

KROS's Sharpe Ratio of -0.39 indicates that for each unit of volatility, it generates -0.39 units of excess return above the risk-free rate. The ratio is calculated using historical daily returns over the past 12 months (as of Jun 23, 2026).

Sharpe uses total volatility (standard deviation) which includes both upside and downside price movements, making it useful for comparing risk-adjusted returns across different assets. For how to read this number and when it can mislead, see Sharpe Ratio Explained.

KROS Sharpe Ratio Rank

KROS Sharpe Ratio Rank: 24.625
Below Average

KROS ranks above 24.6% of all investments in our database based on Sharpe Ratio over the past 12 months, indicating below-average returns relative to volatility. Securities are ranked from 0 (worst) to 100 (best).

What moves the rank

  • Strong returns with low total volatility → Higher rank
  • High volatility (both upside and downside) → Lower rank
  • Consistent returns → Higher rank than volatile returns of same magnitude
  • Sharp drawdowns increase volatility → Lower rank

What you can do with this information

  • Returns may not adequately compensate for volatility taken
  • Consider smaller allocation given below-average risk-adjusted profile
  • Explore higher-ranked investments with better consistency
  • Assess whether the volatility profile aligns with your portfolio goals

KROS Sharpe Ratio Market Positioning

The chart shows KROS's Sharpe Ratio relative to all stocks on our platform, with color zones indicating percentile rankings. Higher ratios indicate better risk-adjusted returns.

  • Red zone (bottom 25%): -0.40 or lower
  • Yellow zone (middle 50%): -0.40 to 1.12
  • Green zone (top 25%): 1.12 or higher
  • Top 1%: 5.70+
  • Median: 0.20 — half of all investments score higher

How it compares to other similar stocks

The table compares Keros Therapeutics, Inc.'s Sharpe Ratio with other stocks in the Biotechnology industry across multiple time periods, showing how KROS's risk-adjusted performance compares to industry peers.

Data shows 1-, 5-, and 10-year periods, plus each stock's all-time average, as of Jun 23, 2026.

SymbolName1Y Sharpe Ratio5Y Sharpe Ratio10Y Sharpe RatioAll Time Sharpe Ratio
RVMDWRevolution Medicines Inc. Warrant10.84
ERASErasca, Inc.9.68
SLGLSol-Gel Technologies Ltd.9.27
CLYMClimb Bio Inc9.25
SYRESpyre Therapeutics Inc.8.35
ORKAOruka Therapeutics, Inc8.22
RLMDRelmada Therapeutics, Inc.7.54
ANROAlto Neuroscience, Inc7.23
LQDALiquidia Corporation7.21
KODKodiak Sciences Inc.6.77
KROSKeros Therapeutics, Inc.-0.39

S&P 500 Index

How to choose period

Historical Sharpe Ratio

The chart shows KROS's rolling Sharpe ratio over time compared to your chosen benchmark. Rising trends indicate improving returns relative to total volatility, while declining trends may signal deteriorating risk-adjusted performance or increased volatility. Use multiple timeframes to distinguish short-term fluctuations from long-term patterns.

Identify market cycles by observing when KROS consistently outperforms (line above benchmark), underperforms (below benchmark), or aligns with the benchmark.

Loading charts...

Sharpe Ratio Calculator

How does KROS fit in your portfolio?

Add your other holdings to see your portfolio's Sharpe Ratio and find out.

Analyze Your Portfolio